Illumina is headquartered in San Diego, California and was founded in 1998 by David Walt, John Stuelpnagel, Anthony Czarnik, Lawrence Bock, and Marck Chee, to develop, manufacture, and commercialize DNA sequencing technologies. The company is a global provider of DNA sequencing instruments, reagents, and services, that serve biotechnology markets such as DNA sequencing, genotyping, gene expression analysis, and proteomics. Illumina's customers are pharmaceutical companies, educational institutions, research scientists, biotechnology companies, and clinical research organizations.
Illumina has two distinct business units. The first focuses on life science related products and services such as DNA sequencing, bead arrays, vera-codes, and PCR technologies. The second unit focuses on the development and sale of technologies related to medical diagnostics.
According to Wired magazine, in 2016 Illumina's DNA sequencing machines perform 90% of global DNA sequencing. The director of global public relations for Illumina in 2016 told reporters, "We are at a tipping point in genomics, where a broad community of scientists and researchers continue to translate the potential of the genome from science to discoveries and applications" and believes DNA sequencing technologies made by Illumina will continue to be in high demand around the world well into the future.
DNA sequencing machines made by Illumina are based off DNA sequencing technologies developed by Solexa in the early to mid 2000's. Illumina acquired Solexa in 2007 for $600 million after Solexa successfully built a next generation sequencing machine that could sequence 1 gigabase (Gb) of data in a single run of the machine.
Illumina Accelerator is the investment arm of Illumina funding early stage genomics companies. They offer early stage companies financial support, mentorship and access to genomic technologies such as sequencing systems, reagents, and lab space.
The Illumina Accelerator runs 2 six month funding cycles each year consisting of up to 5 companies per cycle with access to up to $100,000 in convertible notes from seed investors and a $20,000 unsecured line of credit. Chosen companies agree to give Illumina Accelerator 8% of common stock for participating in their accelerator program.
During each six month funding cycle selected companies are actively coached by mentors at the Illumina Accelerator to develop a custom curriculum for company building, business strategy, technology development, and pitch development. Credits are given to each company for access to Illumina sequencing technologies, and companies can hire scientists at illumina to help with experimental design. At the end of each funding cycle companies meet with venture capitalists affiliated with the Illumina Accelerator to pitch their business ideas and technologies.
Companies also have the opportunity to receive funding from a $40 million dollar pool of funding from the Illumina Accelerator Boost Capital fund. Illumina Accelerator Boost Capital has a deal with Viking Global Investors to match funding dollar-for-dollar for startups managing to raise in between $1 million and $5 million in funding.
Illumina Accelerator's grant competition encourages entrepreneurs to create companies using next generation sequencing technologies. Grant winners are able to spend one week running sequencing experiments for proof-of-concept at Illumina Accelerator. When the grant is awarded it needs to be used within 6-months. The grant also gives entrepreneurs one business coaching session, and two sequencing experiment design meetings with a senior scientist at Illumina.
On August 17, 2017 Illumina Accelerator announced they will collaborating with a personal genomics company called Helix. The partnership seeks to help entrepreneurs develop DNA-driven products and services. Startups accepted into Illumina Accelerator's accelerator program will gain access to Helix's expertise and sequencing platform. The co-founder and senior vice president of Helix, Justin Kao, had the following to say about the partnership "We are proud to collaborate with Illumina Accelerator to stimulate innovation in personal genomics by helping selected startups harness their creativity and build best-in-class DNA-powered products for everyday use".
Illumina was founded by Amanda Cashin.
Head of Illumina Accelerator & Co-Founder
Senior Vice President & General Counsel
Digital Experience Director
Co-Founder, Board Director
Chief Executive Officer
President, Chief Executive Officer
Vice President of Customer Solutions
Co-Founder, Senior Vice President
Vice President Product Management, Strategic Marketing
Executive Vice President, Chief Administrative Officer, & Chief Financial Officer
Chief Technical Officer & Co-Founder
Senior Vice President, Chief Technology Officer
Senior Vice President Corporate Development and General Manager Enterprise Informatics
Executive Vice President. Operations, Products & Strategy
Senior System Engineer
Chief Medical Officer & Interim General Manager
Senior VIce President, Chief Medical Officer
Senior Vice President & General Manager of Enterprise Informatics
Associate Director, Global Clinical Operations
Global Head of Sales, Enterprise Informatics
Senior Vice President, Chief Commercial Officer
$40 million genomics accelerator introduced by Helix and Illumina
Illumina Accelerator explores genomic innovation in Ontario - Ontario Genomics
Illumina Accelerator Frequently Asked Questions
Illumina Might Be Overlooking Its Top Competitor; Here's Why Investors Shouldn't
Illumina, the Google of Genetic Testing, Has Plans for World Domination
The genomics-focused Illumina Accelerator backs five new companies
Documentaries, videos and podcasts
- DNA sequencingThe process of determining the precise order of nucleotides within a DNA molecule.
- CompanyA company, abbreviated 'co.', is a legal entity made up of an association of people, be they natural, legal, or a mixture of both, for carrying on a commercial or industrial enterprise.
- Cluster: Synthetic biologyA cluster of topics related to synthetic biology.
- Business incubator
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- AgricultureCultivation of life forms for food, fiber, biofuel and other products used to sustain life
- GeneticsScience of genes, heredity, and variation in living organisms
- HealthcareDiagnosis, treatment and prevention of disease, illness, and injury
- Illumina VenturesIllumina Ventures is a venture capital firm in California focused on early-stage companies developing applications of genomics. It invests in therapeutics, life science tools, and clinical diagnostics.
- Show More